Clinical Trial Update: Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SHR-1210 (camrelizumab) with radiation as neoadjuvant therapy for resectable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Hangzhou Cancer Hospital | Conditions: Esophageal Neoplasms, Esophageal Diseases | Phase 2 | Status: UNKNOWN